Medicina
Departament
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublicacions en col·laboració amb investigadors/es de GlaxoSmithKline (United Kingdom) (38)
2023
-
A randomised trial of anti-GM-CSF otilimab in severe COVID-19 pneumonia (OSCAR)
The European respiratory journal, Vol. 61, Núm. 2
-
Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)
eClinicalMedicine, Vol. 57
2022
-
An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension
Pulmonary Circulation, Vol. 12, Núm. 1
-
Non-typeable Haemophilus influenzae-Moraxella catarrhalis vaccine for the prevention of exacerbations in chronic obstructive pulmonary disease: a multicentre, randomised, placebo-controlled, observer-blinded, proof-of-concept, phase 2b trial
The Lancet. Respiratory medicine, Vol. 10, Núm. 5, pp. 435-446
2021
-
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies
HIV Research and Clinical Practice, Vol. 23, Núm. 1, pp. 9-14
2020
-
Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials
Journal of acquired immune deficiency syndromes (1999), Vol. 85, Núm. 3, pp. 325-330
-
Characteristics and treatment regimens across ERS SHARP severe asthma registries
European Respiratory Journal, Vol. 55, Núm. 1
-
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: A phase 3, randomized clinical trial
Clinical Infectious Diseases, Vol. 70, Núm. 2, pp. 181-190
2019
-
Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
Pulmonary Circulation, Vol. 9, Núm. 2
-
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
The Lancet, Vol. 393, Núm. 10167, pp. 143-155
-
Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster after Autologous Stem Cell Transplantation: A Randomized Clinical Trial
JAMA - Journal of the American Medical Association, Vol. 322, Núm. 2, pp. 123-133
-
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis
The Lancet Infectious Diseases, Vol. 19, Núm. 9, pp. 988-1000
-
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial
Cancer, Vol. 125, Núm. 8, pp. 1301-1312
-
Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study
HIV Research and Clinical Practice, Vol. 20, Núm. 4-5, pp. 111-122
-
Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor–experienced adult patients with PNH: The 302 study
Blood, Vol. 133, Núm. 6, pp. 540-549
-
Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary
European Heart Journal: Acute Cardiovascular Care, Vol. 8, Núm. 8, pp. 745-754
2018
-
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
The Lancet, Vol. 392, Núm. 10157, pp. 1519-1529
2016
-
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy
European Journal of Cancer, Vol. 56, pp. 85-92
2015
-
CEREBEL (EGF111438): A phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer
Journal of Clinical Oncology, Vol. 33, Núm. 14, pp. 1564-1573
-
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer
European Journal of Cancer